Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

(2020) Alexander M. M. Eggermont et al.   JAMA Oncology

Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis

(2020) Shira Peleg Hasson et al.   Clinical Research in Cardiology

Cardiovascular toxicities associated with immune checkpoint inhibitors

(2019) Jiun-Ruey Hu et al.   CARDIOVASCULAR RESEARCH

Myocarditis in the Setting of Cancer Therapeutics

(2019) Marc P. Bonaca et al.   CIRCULATION

Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab

(2019) S. D. Saibil et al.   Current Oncology

Successful therapy for autoimmune myocarditis with pembrolizumab treatment for nasopharyngeal carcinoma

(2019) Qingqing Wang et al.   Annals of Translational Medicine

Nivolumab-induced Myocarditis Successfully Treated with Corticosteroid Therapy: A Case Report and Review of the Literature

(2019) Keisuke Matsuo et al.   INTERNAL MEDICINE

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

(2019) Satya Das et al.   Journal for ImmunoTherapy of Cancer

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

(2018) Syed S. Mahmood et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

(2018) Javid J Moslehi et al.   LANCET

Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non‐Small Cell Lung Cancer Patients

(2018) Matteo Sarocchi et al.   ONCOLOGIST

Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action

(2018) Tomas G. Neilan et al.   ONCOLOGIST

Immune Checkpoint Inhibitor‐Associated Myocarditis

(2018) Sarju Ganatra et al.   ONCOLOGIST

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

(2018) Koji Haratani et al.   JAMA Oncology

Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer

(2018) Mehdi Touat et al.   NEUROLOGY

Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease

(2017) Alida L.P. Caforio et al.   EUROPEAN HEART JOURNAL

Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab

(2017) Alexandre Reuben et al.   OncoImmunology

Smoldering myocarditis following immune checkpoint blockade

(2017) Timothy G. Norwood et al.   Journal for ImmunoTherapy of Cancer

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

(2017) I. Puzanov et al.   Journal for ImmunoTherapy of Cancer

Fulminant lymphocytic myocarditis associated with orbital myositis and diaphragmatic paralysis

(2016) Oh Hong Kwon et al.   CARDIOVASCULAR PATHOLOGY

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

(2016) Douglas B. Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

(2015) M. Freeman-Keller et al.   CLINICAL CANCER RESEARCH

Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis

(2015) Hansje-Eva Teulings et al.   JOURNAL OF CLINICAL ONCOLOGY

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma

(2015) Heinz Läubli et al.   Journal for ImmunoTherapy of Cancer